Latest News and Press Releases

2026 SteelPower performance report covers male enhancement formula details, ingredient research context, pricing, and guarantee disclosures.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

SonusZen hearing support ingredients, Sonus Zen tinnitus supplement formulation transparency, B vitamin research, auditory health claims for 2026

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...

Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient...

GREAT NECK, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that net income for the year ended December 31, 2025 was...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with...

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

Notice of ordinary and extraordinary shareholders’ meetings Umicore invites its shareholders to participate in the ordinary and extraordinary shareholders’ meetings, which will be held on Thursday,...